FREE Top 5 ASX Stocks for November 2026 Download Free Report
ASX 200

Pro Medicus Signs $128M 10-Year NYC Health Deal – Can the Growth Story Continue?

(Image source: Canva)
Team Veye   November 20, 2026

The increasing use of AI and technology is becoming an integral part in the healthcare industry. Pro Medicus Limited is a company that works in this area. Its new contracts and impressive financial performance provide the company with opportunities to grow further.

Pro Medicus Limited (ASX: PME) is an Australian healthcare informatics company that provides a full range of medical imaging software and services to hospitals, imaging centers and healthcare groups in Australia, North America and Europe. The company has recently come into attention after signing a major $128M contract for a period of 10 years with NYC Health + Hospitals. It has a market capitalization of $20.11B. This has raised interest in whether the company can continue this growth trajectory.

The NYC Health Deal

On 20 November 2026, Pro Medicus announced that Visage Imaging, Inc., which is its wholly-owned US subsidiary, has signed a 10-year contract worth $120M with NYC Health + Hospitals. Under this contract, PME will implement its full cloud-based Visage 7 platform throughout NYC Health + Hospitals and provide a unified diagnostic imaging platform. Further, Visage will convert the Hospitals’ legacy PACS archives to Visage 7 Open Archive. It will also provide enterprise distribution of images integrated with the Hospitals’ electronic health record. This rollout is expected to go live in late Q3 2027.

Pro Medicus’ Financial Performance

PME has recorded impressive growth in its financial performance. The company’s revenue increased by 22.9% from $213M in FY25 to $261.7M in FY26. Its underlying EBIT and underlying net profit after tax also increased by 24.4% and 24.1% to $196.1M and $144.7M respectively in FY26. Its reported net profit after tax surged by 130.3%, from $115.2M in FY25 to $265.3M in FY26. At the end of FY26, its cash reserves stood at $216.1M, representing a 23.8% rise as compared to previous year.  For financial year 2026, the company also paid a dividend of 69 cents per share.

Can the Growth Story Continue?

Aside from this contract, the company also secured some other contracts involving its Visage 7 platform. In August 2026, it signed a 7-year contract worth $25M with Valley Health. In October 2026, PME signed a contract worth $24M for a 7-year period with Logan Health followed by a $43M contract for 7-years with Virtua Health.

Alongside this, PME also signed 10 new contracts and renewed 6 contracts. As of FY26, its Total Contract Value was $551M. The company is focused on expanding its customer base, launch new products and enter into new areas such as cardiology, digital pathology and AI optimized Reporting module.

(Source: Company Announcements)

Unlock Full Article

Enter your details to continue reading

Get your Free Report on Top 5 ASX stocks for 2026
💬

Get Your Free Report on Top 5 ASX Stocks on WhatsApp

Instant Access. No Credit Card Required.

Receive on WhatsApp

TOP ASX STOCKS WORTH WATCHTING

  • ✓ Instant Access
  • ✓ No Credit Card Required
  • ✓ Free to join · No spam
Get Free Report on WhatsApp

Free to join · No spam · Unsubscribe anytime

By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.

EXCLUSIVE OFFER

7 day free trial

Start Free Trial
7‑day free trial

ASX Stock Research & Recommendations — 7‑day free trial

Independent, analyst‑driven insights.

  • Stock of the week report
  • Daily Analysis Report
  • No credit card required
General information only. Not financial advice.

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.